Veradermics, Incorporated - Asset Resilience Ratio
Veradermics, Incorporated (MANE) has an Asset Resilience Ratio of 55.79% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Veradermics, Incorporated leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Veradermics, Incorporated's Asset Resilience Ratio has changed over time. See how leveraged is Veradermics, Incorporated's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Veradermics, Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Veradermics, Incorporated.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $222.38 Million | 55.79% |
| Total Liquid Assets | $222.38 Million | 55.79% |
Asset Resilience Insights
- Very High Liquidity: Veradermics, Incorporated maintains exceptional liquid asset reserves at 55.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Veradermics, Incorporated Industry Peers by Asset Resilience Ratio
Compare Veradermics, Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Camurus AB
ST:CAMX |
Biotechnology | 78.61% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Disc Medicine Inc.
NASDAQ:IRON |
Biotechnology | 85.48% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
Annual Asset Resilience Ratio for Veradermics, Incorporated (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Veradermics, Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 78.69% | $120.10 Million | $152.62 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $59.38 Million | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more